Investment Thesis
Intellia demonstrates severe financial stress with $100.5M operating losses on $15M revenue and $117.3M annual cash burn, providing only ~1.2 years of runway at current rates. Despite a strong balance sheet with $620.9M equity and no debt, the fundamental unprofitability (-639.5% net margin) indicates a pre-revenue stage business model far from viability. Continued dependence on capital raises will significantly dilute shareholders before any clear path to profitability emerges.
Strengths
- Debt-free balance sheet with $620.9M stockholders' equity eliminates solvency risk
- Excellent liquidity position with 6.10x current ratio enabling sustained R&D spending
- Positive revenue growth trajectory at 16.9% YoY indicating emerging market acceptance
- Minimal interest burden and financial obligations reducing near-term distress probability
- Insider activity (7 Form 4 filings) demonstrates management stake in company direction
Risks
- Unsustainable cash burn of $117.3M annually against $134.7M cash reserves yields ~1.2 year runway
- Operating losses of $100.5M represent -668% margin on $15M revenue, demonstrating non-viable unit economics
- Revenue base is immaterial relative to operating expenses; requires >10x revenue growth to approach breakeven
- Mandatory equity capital raises for survival will create substantial shareholder dilution
- Early-stage biotech with no visibility into clinical trial success, regulatory approval timeline, or commercialization feasibility
Key Metrics to Watch
- Quarterly operating cash burn rate trend and months of runway remaining
- Revenue growth rate, customer concentration, and path to $100M+ annual revenue
- Operating loss reduction trajectory and progress toward gross margin inflection
- Capital raise announcements and resulting shareholder dilution impact
- Clinical pipeline milestones and trial advancement rates affecting long-term viability
Financial Metrics
Revenue
15.0M
Net Income
-96.2M
EPS (Diluted)
$-0.81
Free Cash Flow
-117.4M
Total Assets
758.8M
Cash
134.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-668.1%
Net Margin
-639.5%
ROE
-15.5%
ROA
-12.7%
FCF Margin
-780.3%
Balance Sheet & Liquidity
Current Ratio
6.10x
Quick Ratio
6.10x
Debt/Equity
0.00x
Debt/Assets
18.2%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T09:47:23.355624 |
Data as of: 2026-03-31 |
Powered by Claude AI